PDCD1 and nasopharyngeal carcinoma: The ORR was relatively greater than that of other PD-1 antibodies, like nivolumab (ORR: 20.5%) [30], pembrolizumab (ORR: 25.9%) [31], camrelizumab (ORR: 28.2%), and toripalimab (ORR: 23%) for prior-treated recurrent or metastatic NPC [32, 33].